ReviewFrontiers in cellular and infection microbiology2025
MALDI-TOF MS in conjunction with machine learning: toward a new era for antimicrobial susceptibility testing.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial Intelligence and Bioengineering Approaches for Antimicrobial Resistance Prediction.Medicina (Kaunas, Lithuania) · 2026Review
- Rapid identification of carbapenem-resistant Acinetobacter baumannii based on MALDI-TOF mass spectrometry and machine learning.BMC microbiology · 2026Article
- Artificial Intelligence in Infectious Disease Care: Selected Applications in Tuberculosis, Sepsis, and Antimicrobial Stewardship.Diagnostics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global public health is formidably threatened by antimicrobial resistance (AMR). Antimicrobial susceptibility testing (AST) is characterized by its long duration. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is notable for its rapid analysis and cost-effectiveness. However, its role in AST has not been fully explored. In recent years, new opportunities for predicting AMR using MALDI-TOF MS data have been provided by the development of machine learning (ML) technologies. The research progress in using MALDI-TOF MS combined with ML for AMR testing is surveyed by this review, and critical steps including raw MALDI-TOF MS data acquisition, raw data preprocessing, algorithm selection, hyperparameter optimization, among others. It was found by us that the true resistance status can be comprehensively reflected by large-scale datasets, but effective management of high-dimensional data challenges is required. Algorithm performance can be enhanced by identifying the optimal combination of hyperparameters. Better predictive performance than individual models can be achieved by stacking ensemble learning methods. Model performance and generalizability can be more effectively assessed by metrics such as the Area Under the Receiver Operating Characteristic Curve (AUROC). The decision-making process can be understood by users with the help of model interpretation, thereby increasing model transparency and acceptability. Insufficient sample size, inadequate data standardization, and limited model generalizability are included in the current challenges. Continuously optimized, the integration of MALDI-TOF MS and ML is poised to open future avenues for rapid and accurate AMR prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.